Man Group plc Acquires New Holdings in ICU Medical, Inc. $ICUI

Man Group plc bought a new position in ICU Medical, Inc. (NASDAQ:ICUI) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 4,057 shares of the medical instruments supplier’s stock, valued at approximately $595,000.

Several other hedge funds also recently modified their holdings of the business. AQR Capital Management LLC raised its holdings in shares of ICU Medical by 2.5% during the 1st quarter. AQR Capital Management LLC now owns 9,360 shares of the medical instruments supplier’s stock valued at $1,297,000 after purchasing an additional 229 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in ICU Medical by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,764 shares of the medical instruments supplier’s stock worth $1,772,000 after buying an additional 560 shares during the last quarter. United Services Automobile Association bought a new position in ICU Medical during the first quarter valued at about $218,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of ICU Medical by 32.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 68,211 shares of the medical instruments supplier’s stock worth $9,472,000 after buying an additional 16,680 shares during the last quarter. Finally, Intech Investment Management LLC boosted its stake in shares of ICU Medical by 38.6% during the 1st quarter. Intech Investment Management LLC now owns 11,938 shares of the medical instruments supplier’s stock worth $1,658,000 after acquiring an additional 3,326 shares in the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

Insider Buying and Selling

In related news, COO Christian Voigtlander sold 8,929 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $182.93, for a total value of $1,633,381.97. Following the completion of the transaction, the chief operating officer directly owned 37,377 shares of the company’s stock, valued at $6,837,374.61. This trade represents a 19.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Ben Sousa sold 2,250 shares of the stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $178.32, for a total transaction of $401,220.00. Following the completion of the transaction, the insider owned 3,076 shares of the company’s stock, valued at approximately $548,512.32. This represents a 42.25% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 21,830 shares of company stock worth $3,905,003. 2.10% of the stock is currently owned by corporate insiders.

ICU Medical Stock Performance

NASDAQ:ICUI opened at $166.29 on Friday. The firm’s 50-day moving average is $166.96 and its 200-day moving average is $144.70. The company has a market cap of $4.16 billion, a price-to-earnings ratio of 140.92, a PEG ratio of 2.15 and a beta of 0.75. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.21 and a current ratio of 2.43. ICU Medical, Inc. has a 52-week low of $112.50 and a 52-week high of $192.85.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.46. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The business had revenue of $547.88 million during the quarter, compared to analysts’ expectations of $533.44 million. During the same quarter last year, the company earned $2.10 earnings per share. The firm’s revenue was up .5% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Equities research analysts anticipate that ICU Medical, Inc. will post 7.19 earnings per share for the current year.

Analyst Upgrades and Downgrades

ICUI has been the topic of a number of recent analyst reports. Piper Sandler raised their price objective on ICU Medical from $163.00 to $195.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $200.00 price target on shares of ICU Medical in a research report on Friday, August 7th. Sanford C. Bernstein cut ICU Medical to a “market perform” rating in a research report on Monday, June 15th. Wall Street Zen upgraded ICU Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Finally, Zacks Research lowered ICU Medical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, ICU Medical has a consensus rating of “Moderate Buy” and an average price target of $192.80.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.